Primary Care Providers Perspectives of GLP-1 Receptor Agonists to Manage Recurrent Weight Gain after Metabolic Bariatric Surgery – a Qualitative Study
Open Access
- 26 November 2025
- journal article
- research article
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (1) , 193-203
Abstract
Introduction: Recurrent weight gain after metabolic bariatric surgery (MBS) affects 20–25% of patients, with research indicating that up to 87% of patients experience some post-MBS weight gain. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly being used to manage obesity in primary care. However, there remains a gap in understanding primary care providers (PCPs) perspectives on GLP-1RAs in the context of MBS. Methods: For this qualitative study, we recruited primary care providers (PCPs) ( n = 38) from the United States and Sweden who had experience providing healthcare services in primary care after MBS. Individual semi-structured interviews were conducted between September 2024 and March 2025. We analyzed the transcribed interviews with reflexive thematic analysis. Results: The primary theme “GLP-1RAs – Navigating Between Breakthrough and Uncertainty” captures PCPs’ perception of the advent of GLP-1RAs as beneficial, while characterizing their uncertainty regarding GLP-1RA use in post-MBS care. PCPs welcomed the emergence of a new tool to address recurrent weight gain. However, patient requests for GLP-1RAs raised concerns about primary care prescription resources and access due to systematic barriers. PCPs identified a need for more knowledge and experience with GLP-1RA use post-MBS. They also recognized the changing role of MBS in treating obesity. Conclusion: PCPs perceived GLP-1RAs as a promising and effective tool for addressing recurrent weight gain after MBS, and that care options for patients had improved. Systematic barriers were perceived to have a negative impact on the effectiveness of treatment. More expert guidance and support to effectively treat patients with GLP-1RAs after MBS is needed.Keywords
Funding Information
- Karolinska Institute
This publication has 29 references indexed in Scilit:
- Integrative Strategies in Primary Care: Addressing Recurrent Weight Gain Post‐Metabolic and Bariatric SurgeryObesity Science & Practice, 2025
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysisObesity Surgery, 2025
- The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysisObesity Surgery, 2025
- Perceptions of Obesity Among Healthcare Professionals and Policy Makers in 2023: Results of the Global OPEN SurveyObesity Science & Practice, 2025
- Therapeutic Options for Recurrence of Weight and Obesity Related Complications After Metabolic and Bariatric Surgery: An IFSO Position StatementObesity Surgery, 2024
- Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and MortalityJAMA Network Open, 2024
- Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonistsObesity Science & Practice, 2024
- 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric SurgeryObesity Surgery, 2022
- Definitions of Long-Term Weight Regain and Their Associations with Clinical OutcomesObesity Surgery, 2019
- Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and ObesityJAMA, 2019